ReviewRSC advances2023
Marine organisms as potential sources of natural products for the prevention and treatment of malaria.
Review in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Review
- Molecular identification and biological activity of a red sea bacterial isolate.BMC microbiology · 2026Article
- Article
- Cortistatin and plakinamine steroidal alkaloids from the marine sponges of the genusRSC advances · 2025Review
- Emerging trends and new developments in global research on artemisinin and its derivatives.Heliyon · 2025Article
- Marine Natural Products as Novel Treatments for Parasitic Diseases.Handbook of experimental pharmacology · 2025Review
- Targeting EGFR allosteric site with marine-natural products ofCurrent research in structural biology · 2024Article
- Anti-Atopic Dermatitis Activity ofMarine drugs · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vector-borne diseases (VBDs) are a worldwide critical concern accounting for 17% of the estimated global burden of all infectious diseases in 2020. Despite the various medicines available for the management, the deadliest VBD malaria, caused by
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.